Although the history of the Fresenius family's link to health and pharmaceuticals goes back to the 18th century, we can trace the company's roots back to 1462, when the Hirsch Pharmacy opened in Frankfurt, Germany. Fresenius Kabi as a company began life in 1999. Since then, the company has steadily grown to such an extent that we are now a leading power specialising in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition - in the UK and the Republic of Ireland.
Fresenius Kabi is formed by combining Fresenius Group's Pharma division with the infusion solution business acquired from Pharmacia & Upjohn (Kabi). The new company offers a comprehensive product and service portfolio worldwide for hospitals and patients at home.
The birth of Calea UK, an independently run business supported by Fresenius Kabi as the parent company. Calea provides a very personal homecare service in a wide range of therapy areas. At the same time we have the support of the world's most talented and experienced organisation providing medicines and technologies for critically and chronically ill patients.
We move to a purpose-built site in Runcorn, combining Fresenius Kabi and Calea, creating a 'One Company Culture'. The site houses our HQ offices, Warehousing and Distribution facilities under one roof. We begin building our state-of-the-art Aseptic Compounding and Dispensing Unit.
As well as providing all the practical and logistical benefits, the new facility was designed to uphold the company's status as a leading healthcare provider and a major force in the UK market.
We open our new regulated Aseptic Manufacturing and Dispensing Unit (ASU). This enables us to become the preferred supplier for a full range of Aseptic products in the UK. It's MHRA approved and regulated and houses the largest suite of clean rooms in the UK.
Fresenius Kabi acquires Fenwal, a global blood technology company dedicated to supporting transfusion medicine and cell therapies. The combination of both businesses creates not only a major player with exceptional treatment opportunities, it creates a global leader.